Home NDC 82448-260 Gomekli
Product NDC 82448-260
11-digit product format 824480260
Labeler code 82448
Product ID 82448-260_5132f76b-c3da-4831-833c-c48cb8eee26a
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name mirdametinib
Dosage form CAPSULE
Route ORAL
Labeler SpringWorks Therapeutics, Inc.
Application NDA219389
Marketing category NDA
Marketing start 2025-02-11
Substance MIRDAMETINIB
Active strength 2 mg/1
Pharmacologic classes Kinase Inhibitor [EPC], Mitogen-Activated Protein Kinase Kinase 1 Inhibitors [MoA], Mitogen-Activated Protein Kinase Kinase 2 Inhibitors [MoA]
NDC exclude flag No
Listing certified through 2027-12-31
Current FDA listing Yes Source provenance: Browse the complete Orange Book source catalog · source snapshot 43 .
Orange Book products# Current product rows page 1 of 1 · 2 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N219389-001 GOMEKLI MIRDAMETINIB 1MG CAPSULE / ORAL RLD 2025-02-11 N219389-002 GOMEKLI MIRDAMETINIB 2MG CAPSULE / ORAL RLD, RS 2025-02-11
Orange Book patents# Current patent rows page 1 of 1 · 39 matching rows.
Orange Book exclusivity# Current exclusivity rows page 1 of 1 · 4 matching rows.
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-09-14 22:38:34 2026-08 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 caaa826d4ba7…2026-08-18 06:07:40 2026-07 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 caaa826d4ba7…2026-02-19 14:30 UTC 2026-02 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 011fe1cb6892…2026-02-19 14:30 UTC 2026-02 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 31067a03dcf5…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 6a471c1ec25d…2025-08-23 18:47 UTC 2025-08 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 fd3edfee7708…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 fd3edfee7708…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219389-001 GOMEKLI 1MG CAPSULE / ORAL RLD 2025-02-11 a50c72e98297…2026-07-26 02:55 UTC · 3 captures of this ZIP 2026-06 N219389-002 GOMEKLI 2MG CAPSULE / ORAL RLD, RS 2025-02-11 a50c72e98297…
Observed Orange Book patent history# Patent history page 1 of 7 · 247 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Patent Expiration Use code Coverage / status Submission date Source SHA-256 2026-09-14 22:38:34 2026-08 N219389-001 11066358 2041-02-17 Drug substance 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11084780 2041-02-17 Drug substance 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11453641 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11806321 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11819487 2041-02-17 U-4590 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12011424 2041-02-17 U-4595 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12037306 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12263146 2041-02-17 U-4130 2025-04-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12275688 2041-02-17 U-4130 Drug product 2025-04-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12295925 2041-02-17 U-4590 2025-05-15 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11839595 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11883375 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12220390 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12257215 2043-03-16 U-4130 2025-04-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12324791 2043-03-16 U-4591 2025-06-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 11806322 2043-04-09 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12661330 2044-02-05 U-4130 2026-07-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12029711 2044-03-15 U-4130 Drug product 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12383517 2044-03-15 U-4130 Drug product 2025-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-001 12390430 2044-10-10 U-4130 2025-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11066358 2041-02-17 Drug substance 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11084780 2041-02-17 Drug substance 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11453641 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11806321 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11819487 2041-02-17 U-4590 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12037306 2041-02-17 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12263146 2041-02-17 U-4130 2025-04-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12275688 2041-02-17 U-4130 Drug product 2025-04-17 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12295925 2041-02-17 U-4590 2025-05-15 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11839595 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11883375 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12220390 2043-03-16 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12257215 2043-03-16 U-4130 2025-04-03 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12324791 2043-03-16 U-4591 2025-06-16 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 11806322 2043-04-09 U-4130 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12661330 2044-02-05 U-4130 2026-07-02 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12029711 2044-03-15 U-4130 Drug product 2025-02-14 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12383517 2044-03-15 U-4130 Drug product 2025-08-20 84e616aacf4f…2026-09-14 22:38:34 2026-08 N219389-002 12390430 2044-10-10 U-4130 2025-08-20 84e616aacf4f…2026-08-18 06:07:40 2026-07 N219389-001 11066358 2041-02-17 Drug substance 2025-02-14 caaa826d4ba7…
Observed Orange Book exclusivity history# Reported adverse events (FAERS/openFDA)# Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
Finished product Yes
Brand name base Gomekli
Listing expiration 2027-12-31 Active Ingredients# Ingredient, Strength table Ingredient Strength MIRDAMETINIB 2 mg/1
DailyMed Product Concepts# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 82448-260-42 Gomekli 42 in 1 BOTTLE CAPSULE 42 6 82448-260-84 Gomekli 84 in 1 BOTTLE CAPSULE 84 6
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 82448-260 GOMEKLI (MIRDAMETINIB) CAPSULE GOMEKLI (MIRDAMETINIB) TABLET, FOR SUSPENSION [SPRINGWORKS THERAPEUTICS, INC.] 4 Current NDC, 2 package rows 20250328_4c41bf90-5fa7-4935-a95c-e047ea6bbf8e.zip
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Marketing start Sample Exclude flag Status 82448-260-42 82448026042 42 CAPSULE in 1 BOTTLE (82448-260-42) 42 capsule 2025-02-11 No No Current 82448-260-84 82448026084 84 CAPSULE in 1 BOTTLE (82448-260-84) 84 capsule 2025-02-11 No No Current